Chinmay Jani, Chief Fellow of Hematology and Oncology at Sylvester Comprehensive Cancer Center at the University of Miami, shared a post on X:
“Day 2 evening at TTLC 2026 – had insightful conversation with Dr. Luis E. Raez, Memorial Healthcare System, on the recent approval of subcutaneous amivantamab, its current indications, and clinical advantages: Shorter infusion times and improved convenience may meaningfully impact real-world care delivery for patients with EGFR lung cancer. Full video coming soon!”
Other articles about TTLC on OncoDaily.